FDA Drug recall D-1106-2023
NAD+ 200mg/ml, 10ml vials, Tailor Made Compounding
- FDA Drug
- Class II
- terminated
- Published 2023-08-30
On 2023-08-30 the FDA classified a Class II recall of NAD+ 200mg/ml, 10ml vials, Tailor Made Compounding by Tmc Acquisitions, citing lack of Assurance of Sterility.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-1106-2023 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2023-08-15 |
| Published | 2023-08-30 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Tmc Acquisitions |
| Distribution | US |
Product
NAD+ 200mg/ml, 10ml vials, Tailor Made Compounding.
Reason
Lack of Assurance of Sterility
Identifiers
| code_info | Lot#: 07192307A2, BUD: 11/18/2023 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1106-2023%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.